AOD-9604 vs GLP-1 Agonists (Semaglutide, Tirzepatide) GLP-1 receptor agonists like Semaglutide and Tirzepatide represent the current standard for medication-assisted weight loss, producing dramatic results averaging 15-20% total body weight reduction
Tesamorelin: FDA-approved as Egrifta and Egrifta WR, but only for visceral fat reduction in HIV-associated lipodystrophy
You may not eat enough B12-rich foods if you drink a lot
Treating folate without checking B12 status
Budget-constrained individuals may find better value in research peptides for injection, though this option requires accepting lower quality assurance and navigating legal gray areas
routine B12 level monitoring is generally unnecessary once replacement is established, as levels do not reliably correlate with tissue stores Important safety considerations: Older adults may have impaired renal function, though this rarely affects B12 therapy given its wide safety margin